How Long Does ARTG Inclusion Take in Australia?

A product launch can look ready from a commercial perspective and still be held up by one regulatory question: how long does ARTG inclusion take? The practical answer is that it depends on the device, its classification, the evidence supporting it and whether the application is selected for audit. For planning purposes, ARTG inclusion should be treated as a managed regulatory workstream, not a final administrative step.

For manufacturers, importers and distributors, the key is not simply lodging early. It is lodging a complete, correctly structured application with the right Australian sponsor, conformity assessment evidence and post-market arrangements already in place. That is what gives a launch plan the best chance of staying on schedule.

How long does ARTG inclusion take for medical devices?

There is no single processing period that applies to every Australian Register of Therapeutic Goods (ARTG) inclusion application. Lower-risk medical devices with established overseas conformity assessment evidence may move through the process comparatively quickly when the application is complete and not selected for audit. Higher-risk devices, novel technologies, implantables and in vitro diagnostic devices (IVDs) generally require more detailed scrutiny and should be planned over a longer timeframe.

A useful commercial distinction is between the time needed to prepare an application and the time the Therapeutic Goods Administration (TGA) needs to process it. A straightforward inclusion may be ready to lodge within weeks where the manufacturer’s technical documentation, quality certification and labelling are already aligned. If evidence needs to be remediated, certificates are not recognised, or the intended purpose is unclear, preparation can take considerably longer than the TGA assessment itself.

Once lodged, applications can be included without a substantive audit, or they may be selected for audit. An audit introduces additional assessment stages, TGA questions and response deadlines. In that scenario, the overall timeframe may extend from weeks into several months, particularly where evidence requires clarification or the application concerns a higher-risk device.

Current TGA processing targets and audit timeframes should be checked when building a launch plan, as they can change. They are useful planning indicators, but they are not a guarantee of inclusion by a particular date.

What determines the ARTG inclusion timeframe?

The most significant factor is the device’s regulatory classification. Australia’s medical device framework is risk-based. Class I devices generally face a lighter pathway than Class IIa, IIb and Class III devices, while IVDs follow their own classification structure. The higher the risk and the greater the potential impact on patient safety, the more comprehensive the evidence package is likely to be.

The applicable conformity assessment route also matters. Many overseas manufacturers rely on recognised evidence from an acceptable overseas regulator or notified body. Whether that evidence is current, applicable to the device and suitable for the Australian pathway can materially affect readiness. A certificate that covers a different device family, legal manufacturer or intended purpose can create an avoidable delay.

Audit selection is the other major variable. The TGA may select an application for audit based on device type, classification, regulatory history, the evidence provided or risk-based criteria. Audit is not necessarily a sign that there is a problem with the product. It is, however, a more detailed review, and the sponsor must be ready to provide requested documentation promptly and accurately.

Common causes of delay include inconsistencies between the application and technical documentation, incomplete manufacturer evidence, unclear intended purpose statements, expired certificates, unsupported claims and gaps in the Australian sponsor’s records. These issues can be particularly costly when stock, distributor commitments or marketing activity have already been scheduled around an assumed inclusion date.

The application is only one part of market entry

ARTG inclusion is required before a medical device can generally be supplied in Australia, but it is not the same as a complete market-entry strategy. The legal manufacturer must have appropriate conformity assessment evidence and an established quality management system. The Australian sponsor must be able to meet its statutory obligations, including maintaining records, managing adverse event reporting, responding to TGA requests and supporting recalls where necessary.

Labelling and instructions for use also require careful attention. Claims made in Australian promotional materials must remain within the device’s intended purpose and be supported by the evidence held. A fast inclusion outcome is of limited value if the commercial team later needs to rewrite product claims or delay a campaign because the approved regulatory position was not understood at the outset.

For international businesses, local sponsorship is therefore more than an Australian address. The sponsor carries ongoing accountability for the device on the ARTG. Choosing a sponsor with the capability to coordinate pre-market preparation and post-market compliance reduces the risk of a smooth launch becoming a difficult maintenance exercise later.

A realistic timeline for planning purposes

Rather than asking for one fixed number of days, businesses should map the project in stages. The first stage is regulatory assessment: confirming the product is a medical device, determining its Australian classification, identifying the correct inclusion pathway and reviewing available evidence. For a well-documented device, this can be completed efficiently. For products with borderline claims, software functionality or complex combinations of technologies, classification and pathway advice may require deeper analysis.

The second stage is application preparation. This includes checking the manufacturer details, Global Medical Device Nomenclature information, intended purpose, device descriptions, conformity assessment documentation and sponsor records. It also includes resolving any gaps before lodgement. This stage is under the manufacturer’s and sponsor’s control, which makes it the strongest opportunity to protect the timeline.

The third stage is TGA processing. If the application proceeds without audit, inclusion may occur relatively promptly. If the application is selected for audit, allow for the assessment period plus time to respond to information requests. Responses should not be rushed. A concise, evidence-based response that directly addresses the question is usually more effective than providing large volumes of unstructured documentation.

Finally, allow time after inclusion for practical launch activities: confirming ARTG details, finalising compliant promotional materials, coordinating distribution, briefing customer-facing teams and establishing vigilance processes. These activities can often be prepared in parallel, but products should not be supplied before the relevant ARTG inclusion is in place.

How to reduce avoidable delays

The best way to improve ARTG timing is to treat the application as a quality-controlled submission. Start with a gap assessment against the Australian pathway rather than assuming European Union, United States or other market documentation will automatically translate. International evidence can be highly valuable, but it must match the Australian application and the specific device being supplied.

It is also prudent to confirm the legal manufacturer early. Corporate structures, private-label arrangements and contract manufacturing models can make this less obvious than expected. The entity named in certificates, technical documentation and the ARTG application must be consistent, or the relationship must be clearly supported.

Manufacturers should prepare for audit even when they expect a straightforward inclusion. Keep technical documentation current and accessible, nominate internal subject matter experts who can respond quickly, and agree in advance how questions will be reviewed and approved. A delay of several days while teams locate test reports or reconcile product names can have a disproportionate impact on the overall project.

A capable sponsor can add value here by establishing a clear document list, challenging inconsistencies before lodgement and maintaining a realistic view of risk. Compliance Management Solutions (C|M|S) supports this process with regulatory strategy, TGA sponsorship and practical coordination across the manufacturer’s regulatory, quality and commercial teams.

When should you start the ARTG process?

For a planned Australian launch, start regulatory assessment as soon as the intended purpose, product configuration and target market are sufficiently defined. Do not wait until stock is manufactured, packaging is printed or a distributor has announced a release date. Those decisions can be difficult to reverse if the classification, evidence route or permitted claims later differ from assumptions.

Higher-risk devices, IVDs, products that may require TGA conformity assessment, and devices with novel software or diagnostic claims should be given a longer lead time. The same is true where technical documentation is still being developed or quality certificates are due for renewal. Conversely, a mature, low-risk device supported by clean and applicable evidence may have a shorter path, provided the application is prepared carefully.

The most reliable answer to how long ARTG inclusion will take comes from an early review of the actual device and evidence, not from a generic timeframe. Build in contingency, keep the submission evidence-led, and give the regulatory pathway the same project discipline as manufacturing and commercial launch planning.